|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 5/09/17 American Renal Assocs Holdin… Inc 10-Q 3/31/17 73:5M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 520K
2: EX-10.1 Material Contract HTML 43K
3: EX-10.2 Material Contract HTML 40K
4: EX-10.3 Material Contract HTML 39K
5: EX-10.4 Material Contract HTML 41K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
16: R1 Document and Entity Information HTML 41K
17: R2 Consolidated Balance Sheets HTML 115K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 44K
19: R4 Consolidated Statements of Operations HTML 81K
20: R5 Consolidated Statements of Comprehensive (Loss) HTML 35K
Income
21: R6 Consolidated Statement of Changes in Equity HTML 78K
22: R7 Consolidated Statements of Cash Flows HTML 114K
23: R8 Basis of Presentation and Organization HTML 38K
24: R9 Initial Public Offering HTML 41K
25: R10 Cash HTML 29K
26: R11 Accounts Receivable HTML 28K
27: R12 Fair Value Measurements HTML 91K
28: R13 Accrued Expenses and Other Current Liabilities HTML 37K
29: R14 Variable Interest Entities HTML 29K
30: R15 Noncontrolling Interests Subject to Put Provisions HTML 38K
31: R16 Debt HTML 52K
32: R17 Income Taxes HTML 27K
33: R18 Stock-Based Compensation HTML 64K
34: R19 (Loss) Earnings Per Share HTML 55K
35: R20 Related Party Transactions HTML 35K
36: R21 Commitments and Contingencies HTML 27K
37: R22 Certain Legal Matters HTML 34K
38: R23 Changes in Ownership Interest in Consolidated HTML 38K
Subsidiaries
39: R24 Basis of Presentation and Organization (Policies) HTML 40K
40: R25 Cash (Tables) HTML 34K
41: R26 Fair Value Measurements (Tables) HTML 84K
42: R27 Accrued Expenses and Other Current Liabilities HTML 38K
(Tables)
43: R28 Debt (Tables) HTML 47K
44: R29 Stock-Based Compensation (Tables) HTML 64K
45: R30 (Loss) Earnings Per Share (Tables) HTML 52K
46: R31 Changes in Ownership Interest in Consolidated HTML 35K
Subsidiaries (Tables)
47: R32 Basis of Presentation and Organization (Details) HTML 51K
48: R33 Initial Public Offering (Details) HTML 107K
49: R34 Cash (Details) HTML 29K
50: R35 Accounts Receivable (Details) HTML 30K
51: R36 Fair Value Measurements (Details) HTML 30K
52: R37 Fair Value Measurements - Schedule of fair values HTML 58K
(Details)
53: R38 FAIR VALUE MEASUREMENTS - Fair value rollforward HTML 30K
for tax receivable agreement liability (Details)
54: R39 Accrued Expenses and Other Current Liabilities HTML 41K
(Details)
55: R40 Variable Interest Entities (Details) HTML 24K
56: R41 Noncontrolling Interests Subject to Put Provisions HTML 25K
(Details)
57: R42 DEBT - Schedule of long-term debt (Details) HTML 41K
58: R43 DEBT - Scheduled maturities of long-term debt HTML 40K
(Details)
59: R44 DEBT - Narrative (Details) HTML 51K
60: R45 Income Taxes (Details) HTML 28K
61: R46 STOCK-BASED COMPENSATION - Schedule of Expense HTML 30K
(Details)
62: R47 STOCK-BASED COMPENSATION - Narrative (Details) HTML 48K
63: R48 STOCK-BASED COMPENSATION - Assumptions used for HTML 33K
options granted (Details)
64: R49 STOCK-BASED COMPENSATION - Option activity HTML 54K
(Details)
65: R50 STOCK-BASED COMPENSATION - Restricted stock awards HTML 40K
(Details)
66: R51 (Loss) Earnings Per Share (Details) HTML 56K
67: R52 Related Party Transactions (Details) HTML 58K
68: R53 Commitments and Contingencies (Details) HTML 22K
69: R54 Certain Legal Matters (Details) HTML 28K
70: R55 Changes in Ownership Interest in Consolidated HTML 34K
Subsidiaries (Details)
72: XML IDEA XML File -- Filing Summary XML 121K
71: EXCEL IDEA Workbook of Financial Reports XLSX 67K
10: EX-101.INS XBRL Instance -- ara-20170331 XML 1.02M
12: EX-101.CAL XBRL Calculations -- ara-20170331_cal XML 194K
13: EX-101.DEF XBRL Definitions -- ara-20170331_def XML 428K
14: EX-101.LAB XBRL Labels -- ara-20170331_lab XML 1.34M
15: EX-101.PRE XBRL Presentations -- ara-20170331_pre XML 757K
11: EX-101.SCH XBRL Schema -- ara-20170331 XSD 126K
73: ZIP XBRL Zipped Folder -- 0001498068-17-000035-xbrl Zip 165K
| Exhibit |
1. | I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 of American Renal Associates
Holdings, Inc. (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)) and 15d-15(e)) for the registrant and have: |
(a) | Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(c) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/9/17 | 8-K | ||
| For Period end: | 3/31/17 | |||
| List all Filings | ||||